Last reviewed · How we verify
PTP-01
PTP-01 is a protein tyrosine phosphatase inhibitor that modulates immune cell signaling to enhance anti-tumor immunity.
PTP-01 is a protein tyrosine phosphatase inhibitor that modulates immune cell signaling to enhance anti-tumor immunity. Used for Advanced solid tumors (Phase 3 development).
At a glance
| Generic name | PTP-01 |
|---|---|
| Also known as | MOTYS™, allogeneic human placental tissue particulate |
| Sponsor | University of Virginia |
| Drug class | Protein tyrosine phosphatase inhibitor |
| Target | Protein tyrosine phosphatase (PTP) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
PTP-01 targets protein tyrosine phosphatases, which are negative regulators of T cell receptor signaling. By inhibiting these phosphatases, the drug enhances T cell activation and proliferation, potentially improving anti-tumor immune responses. This mechanism aims to overcome immune suppression in the tumor microenvironment.
Approved indications
- Advanced solid tumors (Phase 3 development)
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (PHASE3)
- Phase 0 Biodistribution of Novel Imaging for Resectable Pancreatic Cancer (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PTP-01 CI brief — competitive landscape report
- PTP-01 updates RSS · CI watch RSS
- University of Virginia portfolio CI